# Revelation Biosciences Posts $5.92 GAAP Loss Per Share in Q3 2026

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/51261
Published: 2026-11-08T01:51:29.000Z
Updated: 2026-11-08T01:51:29.000Z
Section: Business

> Cash and cash equivalents were $9.1 million on Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025.

Revelation Biosciences, Inc. (REVB) posted a GAAP loss of $5.92 per share for the third quarter of 2026. The company had $9.1 million in cash and cash equivalents at quarter-end.

Cash and cash equivalents totaled $9.1 million as of Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025.